Critics Say S. Korea Drug Makers Need To Add Innovative Drugs
This article was originally published in PharmAsia News
Executive SummarySome South Korean pharmaceutical companies can expect to jump in sales as they take advantage of global blockbuster drugs losing their patent protection. Dong A, Hanmi, Yuhan and Greencross have recent generic releases to spur that jump, but smaller firms are expected to fall farther behind, according to an analyst. South Korea's pharmaceutical industry has a chance to remake its tarnished image and expand its share of the global market expected to more than double by 2020, with a 9 percent increase expected in South Korea alone. But critics of the industry say it needs to move beyond generics and make new innovative drugs if it is to take advantage of the expected explosion in the demand for medicines. (Click here for more
You may also be interested in...
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.